Introduction {#s1}
============

Signaling through the insulin pathway is a major regulator of growth in a broad diversity of vertebrates and invertebrates ranging from humans and mice, to worms and flies (Oldham and Hafen, [@B50]; Taniguchi et al., [@B66]; Sutter et al., [@B64]; So et al., [@B59]). It regulates diverse processes such as blood glucose homeostasis, differentiation, growth, and senescence (Tatar et al., [@B67]). The pathway is also frequently misregulated in diseases such as diabetes and different types of cancers. In some cells, insulin regulates the uptake of glucose (Furtado et al., [@B21]), in others it is a general regulator of protein synthesis and cell growth (Colombani et al., [@B12]). Among the great discoveries is the interaction between insulin signaling and the Target of Rapamycin (TOR), which mediates between the insulin signal and the utilization of amino acids in protein synthesis and growth (Brogiolo et al., [@B7]; Oldham and Hafen, [@B50]; Avruch et al., [@B4]; Grewal, [@B24]; Kim and Guan, [@B39]). The insulin network also interacts with members of the FOXO family of transcriptional regulators in the control of cell growth and cell proliferation (Jünger et al., [@B35]; Puig et al., [@B52]; Southgate et al., [@B61]; Tang et al., [@B65]; Snell-Rood and Moczek, [@B58]). The insulin signal is able to stimulate upstream members of Ras/Raf-mediated MAPK cascades (Seger and Krebs, [@B56]), which also lead to cellular growth.

Experimental work to understand the properties and function of the insulin signaling network has tended to focus on the roles of one or two components of the network at a time, for example by knocking out or overexpressing one component and examining the phenotypic effect. The overall network is a conceptual framework built up of a large set of individual experiences and understandings. The network is becoming increasingly complex and it is difficult to know how the various components interact with each other. Experimentally, it is impractical, and in most cases impossible, to control for all potential variables, nor is it possible to determine to what degree an experimental result is a consequence of the particular background in which it was performed. Indeed, the functional consequence of a mutation is largely dependent on the background in which it occurs (Dworkin et al., [@B16]; Chandler et al., [@B10]). Alternatively, if the experiment was done under highly controlled conditions, *in vitro*, on a subset of the system, it is not possible to say how that subset would actually perform when embedded within the more complex network with all its many inputs, interactions, and feedback loops. With very simple systems it is possible to perform thought experiments that examine the logic of a network diagram by simply stepping through it. But when the system is large, with positive and negative feedback loops and a mixture of activating and inhibitory interactions, thought experiments generally fail. In addition, although our understanding of the components and overall structure of signal transduction networks is growing rapidly, the dynamical properties of these networks remain largely unknown. This is important because the explanation of some cellular phenomenon lies not in the components but in the dynamics of the system that led to the phenomenon (Wolkenhauer et al., [@B71]).

A grasp of mechanics and combinatorial possibilities of interactions between signaling molecules is insufficient for understanding cellular responses or changes in physiological states. This is because the set of interactions that actually make a functional difference to the cell are a small subset of all the molecular interactions that occur; furthermore, detailed knowledge of local interactions may not be sufficient to understand the global dynamics of the network. Uncovering which components and which dynamics are functionally important is one of the most challenging and important questions for understanding the function and evolution of these signaling networks.

One solution to understanding the properties of a complex network is through mathematical modeling. A mathematical model is nothing more than a quantitative, simplified abstraction of the structure and kinetics of the system. It has two advantages: one is that a mathematical model is completely explicit in what is included and what is not, something an experimental system seldom if ever can be, and second that it allows one to examine whether the network elucidated by experimentation indeed has the properties we assume it does.

There are many approaches to mathematical modeling. Boolean models can describe the logic of a regulatory network, differential equation models can describe the kinetics of a network, and statistical models can describe the patterns of correlation and covariance within a network. Several investigators have developed differential equation-based mathematical models for different portions of the insulin signaling network (Sedaghat et al., [@B55]). Some of these models reproduce selected experimental data well (Sedaghat et al., [@B55]), while others do not attempt to do so and are mostly concerned with the general or the formal properties of the model mechanism (Alon, [@B1]; Vinod and Venkatesh, [@B69]).

The most common problem encountered in building a mathematical model is the dearth of data on the kinetics of the reactions. Most data are static and record the response to an insulin stimulus as "fold-activation" or "percent of control value" or "percent of maximum response." Thus response data are typically reported as scaled quantities. The modeling paradigm we develop here uses scaled variables and is ideally suited to simulate systems in which much of the available data are scaled. We develop a simple network modeling paradigm, inspired by Boolean, genetic, and neural network models (Reinitz and Sharp, [@B53]; Vohradsky, [@B70]; Jaeger et al., [@B31]; Faure et al., [@B20]; Martin et al., [@B44]), that can be used to study the qualitative behavior of complex networks, and apply it to a study of the insulin signaling network. Abstracting the network in a way that is consistent with the available data opens possibilities to reconcile experiments with theory, and thus improves our understanding of the structure and function of signaling networks. A well-validated mathematical model is also a useful adjunct tool for the experimental biologist because it allows for quick and inexpensive testing of alternative hypotheses and may provide suggestions for experimental design.

Methods {#s2}
=======

Structure of the network
------------------------

The insulin signaling network we model is illustrated in Figure [1](#F1){ref-type="fig"}. Insulin binds the insulin receptor (INR), causing it to become phosphorylated and thus activated (Oldham and Hafen, [@B50]). INR has multiple phosphorylation sites which become autophosphorylated upon binding of insulin. The activated INR recruits Insulin Receptor Substrate adaptor proteins (IRS) to the cell membrane. The IRS proteins bind to phosophoinositide 3-kinase (PI3K) and to phosphatidylinositol(3,4,5)-triphosphate (PIP3), and recruit both to the membrane. Biochemically, PI3K becomes activated when it interacts with specific phosphotyrosine motifs in the IRS (Taniguchi et al., [@B66]). Activated PI3K phosphorylates phosphatidylinositol(4,5)-biphosphate (PIP2, also at the cell membrane) into PIP3. The tumor suppressor gene phosphatase tensin homolog deleted on chromosome 10 (PTEN) catalyzes the opposite reaction, dephosphorylating PIP3 to PIP2. PTEN reduces the amount of PIP3, a substrate necessary for the activation of protein kinase B (PKB, also called Akt) (Brazil and Hemmings, [@B6]). Through this mechanism, PTEN is an antagonist to insulin signaling. PTEN is one of the most commonly lost tumor suppressor genes in human cancer. It has relatively high constitutive phosphatase activity (Leslie and Downes, [@B41]). PIP3 facilitates the phosphorylation of protein kinase C (PKC) by PDK1, thus activating PKC (Standaert et al., [@B63]; Taniguchi et al., [@B66]). PIP3 also causes an increase in autophosphorylation of PKC, independent of PDK1, possibly by inducing conformational changes in PKC (Standaert et al., [@B63]). PKC phosphorylates p70 ribosomal kinase S6K (Valovka et al., [@B68]). S6K is involved in the regulation of cell cycle and growth (Montagne et al., [@B46]; Valovka et al., [@B68]). S6K phosphorylates the ribosomal protein S6, and controls the translation of a class of mRNAs that encode ribosomal proteins and elongation factors (Jefferies et al., [@B32]).

![**Insulin and MAPK signaling network**. The acronyms for the components of the network and the rationale for the connectivity are explained in the text.](fphys-04-00245-g0001){#F1}

PIP3 phosphorylates and activates PKB/Akt. PKB has several targets including FOXO, a constitutively active transcription factor (Southgate et al., [@B61]) that is involved in the cellular response to nutritional conditions (Gershman et al., [@B22]). When FOXO is phosphorylated by PKB, it is translocated from the nucleus to the cytoplasm, where it can no longer activate transcription (Essers et al., [@B19]; Aoyama et al., [@B2]). Under extreme starvation conditions, FOXO upregulates the expression (but not the activation) of the INR, increasing cell sensitivity to insulin, and allowing a fast response to insulin after feeding (Jünger et al., [@B35]; Puig and Tijan, [@B53a]).

PKB also activates TOR, a serine/threonine kinase that regulates growth in response to nutritional conditions. TOR is required for response to amino acids (Hara et al., [@B25]). TOR is activated by PKB and positively regulates cell growth via two principal targets, S6K and 4E-BP (Hay and Sonenberg, [@B29]; Sarbassov et al., [@B54]). S6K also phosphorylates the INR, decreasing the interaction of INR with its substrate (IRS) and inhibiting insulin signaling (Harrington et al., [@B26]). The proximal regulator of TOR is a small GTPase, Ras homology enriched in brain (Rheb), which binds to the TOR catalytic domain and activates TOR (Avruch et al., [@B4]). Amino acid withdrawal interferes with the interaction of Rheb and TOR-raptor, indicating that the Rheb-TOR interaction is responsible for the sensitivity of the TOR pathway to the presence or absence of amino acids. Rheb is negatively regulated by the Tuberous sclerosis complex proteins, composed of TSC1 (hamartin) and TSC2 (tuberin) (Manning and Cantley, [@B42]). The disease known as tuberous sclerosis is an autosomal dominant disorder associated with benign tumors that is the result of inherited mutations in the TSC1 or TSC2 genes. PKB phosphorylates TSC2 (Choo et al., [@B11]) inhibiting the function of the TSC1-TSC2 complex (Choo et al., [@B11]). Thus PKB signaling releases the inhibition of Rheb and activates TOR signaling. The TSC complex is necessary for the downregulation of TOR in response to hypoxia (Ellisen, [@B17]).

Many growth factors signal through the MAPK cascade. The MAPK cascade is a highly conserved signaling pathway and is a major regulator of growth and differentiation. MAPK cascades typically have three levels (Huang and Ferrell, [@B30]). The terminal member of the cascade is a MAPK (e.g., ERK, JNK, p34, p42), which is activated by a MAPK kinase (MAPKK: e.g., MEK, EKK), which in turn is activated by a MAPKK kinase (MAPKKK; e.f Raf, Mos). The MAPKKK can be activated in several ways: most commonly by external signals such as epidermal growth factor (EGFR) via a G-protein-coupled receptor complex, and also by insulin signaling (Oldham and Hafen, [@B50]). The terminal MAPK translocates to the nucleus where it phosphorylates transcriptional regulators for protein synthesis, growth and differentiation.

Structure of the model
----------------------

In modeling this system we omit consideration of multiple phosphorylation steps, equilibrium reactions between kinases and phosphatases, and translocations between cytosolic and nuclear compartments. We consider only the activity level of the various kinases and other components in the network. Unlike a Boolean network, in which each element is either on or off, each element in our scheme can have a continuum of activity between zero (inactive) and one (maximum activity). The activity level of a node in the network is a function of activating and inhibitory inputs. We assume that activation follows a sigmoid trajectory, with little activity at low input levels and saturating at high input levels.

The time-dependent activation equation for each node in the network is the logistic $$\frac{dy}{dt} = ay(1 - y/b)$$ where *a* is the rate of increase and *b* is the ceiling. Over time *y* levels off at the value of *b*. Graphs of this time-dependent response, and the effects of parameters *a* and *b*, are shown in Figure [2](#F2){ref-type="fig"}. The value of *b* is a sigmoidal function of input, so that at low input *b* (and consequently the maximum value of *y*) is small and rises sigmoidally to a value of 1 as input increases. The equation for *b* is a solution to the logistic, as follows $$b = \frac{1}{1 + e^{- \frac{\text{input} - 0.5}{c}}}$$ where the 0.5 ensures the inflection point is at an input of 0.5, and *c* sets the steepness of the transition, with smaller values producing a more switch-like transition. The curves are symmetrical around the inflection point. Graphs of this function for different values of *c* are shown in Figure [3](#F3){ref-type="fig"}.

![**Time-dependent sigmoids (effect of parameters *a* and *b*)**. Parameter *a* controls when the response attains saturation. Parameter *b* controls the saturation point of the response.](fphys-04-00245-g0002){#F2}

![**Graphs of the value of *b* in Equation (2) as a function parameter *c***. Parameter *c* controls the steepness of the sigmoid; the smaller *c* is, the steeper the sigmoid.](fphys-04-00245-g0003){#F3}

This pair of functions thus scales the value of *y* between 0 and 1, for a range of inputs that are scaled from 0 to1. The value of *y* then becomes part of the input to the next step in the network. Multiple (activating and inhibiting) inputs are summed as follows: activators are averaged, and inhibitors are averaged and subtracted from the activator mean.

Thus the input function looks like: $$$$ where *W*~*i*~ represent the weight of each activator or inhibitor. The weights were chosen in such a way that the model reproduced experimental data (Sedaghat et al., [@B55]; Danielsson et al., [@B13]). Values for the weights used in the present model, and the values of all other parameters, are given in Table [1](#T1){ref-type="table"}. There is no information available on how multiple inputs are integrated, so we assume a linear weighing scheme. The linear weighing scheme is therefore a hypothesis about how things could work, and as more data become available it might have to be modified. We show that the selection of weights and parameter values in Table [1](#T1){ref-type="table"} is also sufficient to enable the model to reproduce a broad diversity of experimental results.

###### 

**Parameter values and input functions used in the model**.

  **Variable**        **Activators**            **Inhibitors**   **Input function**                                           ***c***   ***a***
  ------------------- ------------------------- ---------------- ------------------------------------------------------------ --------- ---------
  INR                 Insulin, FOXO                              (insulin.^\*^1+ FOXO.^\*^0.144)./2                           0.15      1
  IRS                 INR                       PKB, S6K         INR.^\*^2−(0.1.^\*^PKB + 0.2.^\*^S6K)./2                     0.15      1
  PI3K                IRS                                        IRS.^\*^1                                                    0.2       1
  PIP3                PI3K                                       PI3K.^\*^1                                                   0.2       1
  PKC                 PIP3                                       PIP3.^\*^1                                                   0.25      1
  PKB                 PIP3                      PKC              PIP3.^\*^1−0.5.^\*^PKC                                       0.15      1
  GLUT4               PKC, PKB                                   (PKC.^\*^3 + PKB.^\*^4)./2                                   0.05      1
  TSC                 Constitutive              PKB              1--0.7.^\*^PKB                                               0.1       0.5
  Rheb                Constitutive              TSC              1--0.5.^\*^TSC                                               0.1       1
  TOR                 Rheb, amino acids, PKB    FOXO             (rheb.^\*^3 + 1.^\*^aminoAcids + 2.^\*^PKB)./3--2^\*^FOXO)   0.1       1
  S6K                 TOR, PKC                                   (TOR.^\*^1.5 + PKC.^\*^0.5)./2                               0.1       1
  Protein synthesis   TOR, S6K, MAPKKK                           (S6K.^\*^1 + TOR.^\*^1 + MAPK.^\*^1.2)./3                    0.1       1
  FOXO                Constitutive              PKB              1--0.9.^\*^PKB                                               0.1       0.5
  MAPK                MAPKK                                      MAPKK                                                        0.1       1
  MAPKK               MAPKKK                                     MAPKKK                                                       0.15      1
  MAPKKK              INR, EGF growth factors   MAPK             (egfsignal + PI3K)/2--0.3.^\*^MAPK                           0.2       1

The model consists of a set of coupled equations of the form of Equation (1), one for each node in the network, with the values of *b* represented by Equation (2) and the inputs by Equation (3). Most nodes are inactive unless activated, with the exception of TOR, Rheb and TSC, which are constitutively active unless inhibited. There are three external inputs: insulin, amino acids, and growth factors that activate the MAPK cascade.

Results and discussion
======================

The MAPK cascade and switch-like behavior
-----------------------------------------

The MAPK phosphorylation cascade is one of the most prevalent signal transduction pathways, typically mediating between a G-protein coupled surface receptor for a growth signal and a transcriptional regulator that affects growth and cell proliferation. The MAPK cascade can also be activated by insulin signaling via the stimulation of the upstream kinase (e.g., Raf) via INR (Oldham and Hafen, [@B50]). MAPK cascades have either three or four levels with multiple phosphorylation steps at each level (Huang and Ferrell, [@B30]). This structure sharpens the response to a graded signal and makes the response increasingly more switch-like at successively lower levels of the cascade (Huang and Ferrell, [@B30]). In our model we do not explicitly model phosphorylation and dephosphorylation steps but instead model the transition between an active and inactive kinase, using our sigmoid formalism. Figure [4](#F4){ref-type="fig"} illustrates the behavior of the 3-step MAPK cascade we model to a linear graded input and shows the expected switch-like behavior. The increasing steepness of the response emerges from the fact that each lower step in the cascade is responding to a sigmoidal input in a sigmoidal fashion. MAPK cascades may have a negative feedback regulation by the last to the first member in the cascade (Brondello et al., [@B8]; Keyse, [@B36]; Kholodenko, [@B37]; Asthagiri and Lauffenburger, [@B3]; Nijhout et al., [@B48]). Figure [5](#F5){ref-type="fig"} shows the dose-response behavior of our model when such a feedback is included, using the same kinetic parameters as in Figure [4](#F4){ref-type="fig"}. Including the feedback makes the response of the terminal kinase less switch-like.

![**MAPK cascade simulation shows that the signal becomes more switchlike as it travels down the MAPK cascade, as shown in Huang and Ferrell ([@B30])**.](fphys-04-00245-g0004){#F4}

![**MAPK cascade with negative feedback from MAPK to MAPKKK**. The negative feedback makes the response less switchlike.](fphys-04-00245-g0005){#F5}

Insulin dose-response
---------------------

In our model insulin concentration can vary from zero (no insulin) to 1 (maximum or saturating insulin). Dose-response curves are typically hyperbolic on linear axes and sigmoidal when plotted on a logarithmic x-axis. In our scheme all axes are linear and the linear x-axis must therefore represent a logarithmic insulin concentration scale. The dose-response of INR phosphorylation to insulin in experimental settings spans about 4-orders of magnitude of insulin concentration (from 10^−11^ to 10^−7^ M) (Stagsted et al., [@B62]; Kurtzhals et al., [@B40]; Sedaghat et al., [@B55]; Danielsson et al., [@B13]). Thus on our linear scale 0.25 units correspond approximately to one decade on a logarithmic scale.

Dose-response curves for active IRS, active PI3K, PKB, GLUT4, and MAPK, as functions of insulin concentration are shown in Figure [6](#F6){ref-type="fig"}. The activities are scaled to the maximal response and these relative responses closely resemble the empirical data of Stagsted et al. ([@B62]); Danielsson et al. ([@B13]), except for the response of PKB, which in experimental data appears to saturate at somewhat lower concentrations of insulin than it does in our model.

![**Insulin dose response curves of various components of the insulin and MAPK signaling pathways replicating (Stagsted et al., [@B62]; Sedaghat et al., [@B55]; Danielsson et al., [@B13])**. The GLUT4 transporters are the most sensitive to insulin signaling, and achieve their maximum response at relatively low levels of insulin stimulation (0.4).](fphys-04-00245-g0006){#F6}

Amino acids, protein synthesis, and tor knockout
------------------------------------------------

Normal growth requires, in addition to insulin signaling, amino acid signaling through TOR (Hay and Sonenberg, [@B29]; Martin and Hall, [@B43]; Kim and Guan, [@B39]). In our model, amino acids activate TOR/Raptor directly. In addition, insulin signaling is known to stimulate the import into the cell of neutral amino acids that are handled by the system-A transporter (Kilberg, [@B38]; McDowell et al., [@B45]; Biolo et al., [@B5]; Jones et al., [@B33]). The exact mechanism is not fully understood, and here we model it as an effect of PKC. Thus growth is regulated by three interacting pathways, MAPK, insulin, and TOR (Figure [7](#F7){ref-type="fig"}). MAPK and insulin signaling can stimulate growth autonomously, but TOR requires activation by insulin signaling in order to be sensitive to stimulation by amino acids.

![**(A)** Protein synthesis as a function of MAPK and insulin. MAPK and insulin act synergistically, and the maximum protein synthesis occurs when both pathways are activated. Nevertheless, at low levels of MAPK signaling, insulin is still able to stimulate protein synthesis. **(B)** Same figure but with TOR knockout. The effect of the TOR knockout on protein synthesis is only noticeable when there is weak MAPK signaling (right corner of the figure); when TOR is knocked out and MAPK signaling is low, insulin alone cannot stimulate protein synthesis.](fphys-04-00245-g0007){#F7}

PTEN, a tumor suppressor gene
-----------------------------

PTEN is a well-known tumor suppressor gene, and many cancers are associated with a reduction in PTEN activity (Leslie and Downes, [@B41]; Nassif et al., [@B47]; Song et al., [@B60]). We show with our model that knocking out PTEN increases protein synthesis at lower insulin levels (Figure [8A](#F8){ref-type="fig"}), and increases insulin sensitivity of GLUT4 activation (Figure [8B](#F8){ref-type="fig"}). This is consistent with data showing that PTEN haploinsufficiency increases the probability of developing tumors, and also increases insulin sensitivity (protects against diabetes) (Pal et al., [@B51]). Overexpression of PTEN, by contrast, greatly reduces both proteins synthesis and GLUT4 activation, consistent with its role as a tumor suppressor (Zhao et al., [@B72]).

![**Effect of PTEN over expression and knock-down on the sensitivity of insulin stimulated protein synthesis (A) and GLUT4 activation (B)**. PTEN overexpression reduces the maximum level of protein synthesis, and completely abrogates the response of GLUT4 to insulin stimulation. PTEN underexpression does not have as dramatic an effect, but does increase the sensitivity of protein synthesis in response to insulin especially at high insulin levels. In contrast, the stimulatory effect of PTEN underexpression on GLUT 4 sensitivity is mainly observed at low insulin levels.](fphys-04-00245-g0008){#F8}

FOXO: a regulator of phenotypic plasticity?
-------------------------------------------

Insulin signaling regulates growth and size in response to nutrition (Oldham and Hafen, [@B50]; Grewal, [@B24]), but few morphological traits scale isometrically: morphological traits commonly scale hyper- or hypo-allometrically with size. These scaling relationships must arise from differential sensitivity of tissues to systemic growth factors and nutritional availability.

Recent evidence indicates that differential trait growth is a consequence of differential sensitivity to insulin, regulated by FOXO (Tang et al., [@B65]; Snell-Rood and Moczek, [@B58]; Shingleton and Frankino, [@B57]). Genitalia of flies (Tang et al., [@B65]) and of beetles (Snell-Rood and Moczek, [@B58]) are relatively insensitive to nutrition (or lack thereof). In contrast, wings and horns are more sensitive to nutrition (Tang et al., [@B65]; Emlen et al., [@B18]). In beetles, knockdown of FOXO using RNAi causes slight but significant overgrowth of the genitalia (Snell-Rood and Moczek, [@B58]), indicating that in normal growth conditions, FOXO represses insulin-stimulated growth in that tissue. Loss of FOXO causes genitalia and wings to both scale isometrically with body size (Tang et al., [@B65]), indicating that FOXO is necessary to maintain trait-specific sensitivity to insulin.

In normal growth conditions, increased expression of FOXO decreases body and organ size (Jünger et al., [@B35]; Puig et al., [@B52]). In poor nutritional conditions or in Insulin Receptor (InR) mutants, growth is inhibited, and this reduction in growth is partially rescued by knocking out FOXO (Tang et al., [@B65]). A similar phenomenon has been observed in *C. elegans*: mutants in Daf-2 (INR homolog) arrest growth at the dauer stage, but null mutations in Daf-16 (FOXO homolog) suppress the effects of mutations in Daf-2, rescuing growth (Ogg et al., [@B49]). This suggests that in both flies and worms, FOXO knockout rescues InR mutants.

We tested the model against these predictions. Specifically we tested the following predictions: (1) *FOXO overexpression* should decrease body size/protein synthesis under any nutritional condition. Indeed, Figure [9](#F9){ref-type="fig"} shows the result of overexpressing FOXO: protein synthesis is reduced as a function of all insulin inputs, but the effect is particularly strong at high insulin levels (in good nutritional conditions). (2) *FOXO knockout*. Under high insulin signaling conditions/high nutritional conditions, FOXO knockout should slightly stimulate protein synthesis. Under low insulin signaling conditions, FOXO knockout flies should increase protein synthesis relative to wild type flies. Indeed, Figure [9](#F9){ref-type="fig"} shows the result of knocking out FOXO. Protein synthesis is increased at low insulin levels, indicating that FOXO knockout compensates for poor nutritional conditions. In high nutritional conditions, protein synthesis is close to wild type, if not slightly enhanced, consistent with the slight increase in size of the beetle genitalia in FOXO knock-down animals (Snell-Rood and Moczek, [@B58]). (3) *FOXO and InR double knockout*. InR knockout should reduce protein synthesis, and this reduction should be partially rescued by the FOXO knockout. Indeed, Figure [10](#F10){ref-type="fig"} shows that protein synthesis is strongly reduced in the InR knockout and that protein synthesis is rescued in the double FOXO-InR knockout. Thus, the model is consistent with previous observations and appears to summarize the developmental mechanism by which FOXO regulates sensitivity to insulin input.

![**Effect of overexpression and knockout of FOXO on insulin-stimulated protein synthesis**. FOXO knockout increases protein synthesis especially at low levels of insulin stimulation. On the other hand, FOXO overexpression primarily affects protein synthesis when insulin signaling is high. These two observations can be explained by the fact that FOXO inhibits TOR and this inhibition is inhibited by PKB when insulin is high. At low insulin levels, FOXO should inhibit TOR and protein synthesis, and hence the knockout relieves this inhibition. At high insulin levels, FOXO should be inhibited by PKB and therefore not have an inhibitory effect on protein synthesis, but FOXO overexpression prevents PKB from entirely relieving the constitutive inhibition of protein synthesis by FOXO.](fphys-04-00245-g0009){#F9}

![**FOXO knockout rescues the growth defects of INR mutants**. In an INR deficient mutant, protein synthesis is severely depressed and regulated primarily by MAPK (activation of MAPK is set at 0.1 in this experiment). FOXO knockout alone has no effect on protein synthesis, but can partially rescue protein synthesis in an INR knockout. Protein synthesis values are scaled to those of a "wild type." Input into the MAPK pathway is 0.1.](fphys-04-00245-g0010){#F10}

Hypoxia
-------

Hypoxia decreases body size in a variety of species, although hyperoxia often does not have a symmetrical effect (Harrison et al., [@B28]; Harrison and Haddad, [@B27]). The mechanisms by which hypoxia affect growth and size are incompletely understood. Oxygen affects multiple physiological processes and is sensed by a variety of signaling pathways, including the Hypoxia Inducible Factor (HIF) (Gorr et al., [@B23]) and nitric oxide (NO)/cyclic GMP pathway (Davies, [@B14]).

HIF and HIF targets interact with components of the insulin signaling pathway; specifically, oxygen affects the inhibition of TSC by Akt (Brugarolas et al., [@B9]; Deyoung et al., [@B15]). In normoxic conditions, insulin causes Akt to phosphorylate TSC2. This phosphorylation promotes the binding of TSC2 to its inhibitor 14-3-3 (Deyoung et al., [@B15]), thereby inhibiting the dimerization and activation of the TSC1/2 complex. In response to hypoxia, REDD1 is induced and sequesters the inhibitor 14-3-3. This releases TSC2 to dimerize with TSC1 and thus promote TSC1/2 function and inhibition of TOR. Thus, in low oxygen conditions, protein synthesis is reduced. Because TSC1/2 is already constitutively active at low insulin signaling, the effects of hypoxia on TSC1/2 will be most apparent at high levels of insulin signaling.

Our model shows that low oxygen levels decrease protein synthesis, and the effect is strongest at high levels of insulin (Figure [11](#F11){ref-type="fig"}). The reason for this effect is that at low levels of insulin, Akt is not stimulated, so Akt is not strongly inhibiting TSC, and the removal of this inhibition has no effect. Hypoxia has the strongest effect on growth when insulin signaling (and Akt) activity is high. In our model, hyperoxia only marginally stimulates protein synthesis beyond its normoxic range. This is consistent with the observation that hyperoxia does not have strong stimulating effects on growth and size in a variety of species (including *Drosophila* and *Manduca*). The fact that the effect of hypoxia is a disinhibition could possibly explain the asymmetrical response of growth to hypoxia and hyperoxia. The double inhibition (Akt inhibits TSC, TSC inhibits TOR) is relieved in hypoxia, but it is unclear whether hyperoxia will significantly enhance the inhibition of TSC by Akt. If this inhibition is already strong in normoxia, then hyperoxia provides no additional benefit. This could explain the asymmetrical growth response to hypoxia/hyperoxia observed in many insect species.

![**Effects of oxygen on protein synthesis (growth), mediated by the insulin and TOR signaling pathways are most strongly observed at high insulin signaling levels (\>0.7)**. This suggests that in poor nutritional conditions, hypoxia or hyperoxia are unlikely to have strong effects on growth and size; only in good nutritional conditions will oxygen show an effect. Hypoxia decreases the rate of insulin-stimulated protein synthesis. Hyperoxia causes protein synthesis to reach its saturating rate at a slightly lower level of insulin signaling, so it has a slight stimulatory effect for insulin between 0.7 and 0.8. At levels of insulin signaling \>0.8, hyperoxia provides no additional stimulation of growth because growth rate has attained its maximum.](fphys-04-00245-g0011){#F11}

Conclusions and significance
============================

We have developed a simple and easy-to-implement mathematical model for investigating the logical sufficiency and qualitative behavior of signaling pathways. This model is particularly useful to simulate experimental data that are scaled or normalized, which are the norm in studies of signaling pathways. We use this model to study the behavior of an integrated insulin-TOR-MAPK pathway and compare the results to a broad diversity of experimental data.

Our model provides a simple and easy-to-implement tool for investigating the dynamics of a system that integrates multiple graded inputs and produces a specific output from a set of possible responses. The kinetics of signal transduction pathways are inherently non-linear and our model embraces this nonlinearity by assuming that the strength of a response (e.g., the activation of a kinase), is a sigmoid function of the combined activating and inhibitory inputs, so that at low input there is no response and at high input the response saturates. The model correctly simulates the ultrasensitivity and switch-like behavior of the MAPK cascade. We show that the model also correctly simulates published dose-response curves of INR, PKC, and GLUT4 to insulin input.

We used the model to simulate several experimental observations. TOR has been widely described as a "sensor" for amino acid input and inactivation of TOR by mutation or by rapamycin reduces growth and body size. When we inactivated TOR in our model we found a reduction in insulin-induced protein synthesis (which we use as a proxy for growth), but, as expected, no effect on MAPK-induced protein synthesis. Thus in cases where growth is controlled jointly by insulin and MAPK signaling, the effect of TOR will depend on the relative role of insulin.

Growth depends not only on hormone signaling but also on an adequate supply of amino acids. Amino acids can directly stimulate the TOR branch of the insulin signaling pathway, but insulin signaling also enhances the uptake of certain amino acids. In our model we found a hyperbolic relationship between amino acid availability and S6K activity in the presence of constant insulin signaling, but no unique effect of amino acids on protein synthesis. Protein synthesis required both insulin and amino acids, but increasing amino acid levels did not increase protein synthesis under constant insulin. In accord with experimental findings we found that overexpression of FOXO decreased insulin-stimulated protein synthesis, whereas a FOXO knockout made protein synthesis more sensitive to insulin levels. Likewise, knockout of FOXO can rescue protein synthesis deficiency caused by an INR knockout. Finally, knockout of PTEN and TSC, both well-known tumor suppressors, greatly increased insulin-driven protein synthesis.

The network we simulated here leaves out most of the biochemical details of the insulin and MAPK signaling pathways, and thus can only simulate the qualitative behavior of the network. Even so, the fit to experimental data is excellent (which are typically also qualitative), which suggest that the structure of the network, and the way in which we modeled it, are sufficient to explain the phenomena we studied here.

A natural question that arises when developing a mathematical model is whether all the necessary players and all their interactions have been included. No network is ever complete, and investigators continually find new players and new interactions. But it is not always clear whether each newly discovered item is critical for the normal operation of the network, or whether it is important only under a particular set of conditions, or whether it has only a minor effect. Moreover, investigators often publish small abbreviated models of hypothetical mechanism suggested by their experimental data but seldom investigate whether the proposed mechanism is sufficient to produce the observed behavior. The current modeling paradigm provides a simple tool to do such a test. One of the uses of a mathematical model is to investigate whether such a hypothetical network actually has the expected behavior. A mathematical model can say whether the system that is being modeled is sufficient to produce the observed biological behaviors found under experimental conditions. And when this is not the case, experimentation with the model can often lead the way to discovery of what is missing.
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